Compare · CHWY vs LOGC
CHWY vs LOGC
Side-by-side comparison of Chewy Inc. (CHWY) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHWY and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
- CHWY is the larger of the two at $8.57B, about 175.7x LOGC ($48.8M).
- CHWY has been more active in the news (9 items in the past 4 weeks vs 1 for LOGC).
- CHWY has more recent analyst coverage (25 ratings vs 5 for LOGC).
- Company
- Chewy Inc.
- ContextLogic Inc.
- Price
- $20.92-2.86%
- $7.05+1.00%
- Market cap
- $8.57B
- $48.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Catalog/Specialty Distribution
- Catalog/Specialty Distribution
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 9
- 1
- Recent ratings
- 25
- 5
Chewy Inc.
Chewy, Inc., together with its subsidiaries, engages in the pure play e-commerce business in the United States. The company provides pet food and treats, pet supplies and pet medications, and other pet-health products, as well as pet services for dogs, cats, fish, birds, small pets, horses, and reptiles through its chewy.com retail Website, as well as its mobile applications. It offers approximately 70,000 products from 2,500 partner brands. The company was founded in 2010 and is headquartered in Dania Beach, Florida. Chewy, Inc. is a subsidiary of PetSmart, Inc.
ContextLogic Inc.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest CHWY
- Director Star James A was granted 10,665 shares (SEC Form 4)
- Director Nesbitt Martin H. was granted 10,665 shares (SEC Form 4)
- Director Goldhaber Nathaniel was granted 10,665 shares (SEC Form 4)
- Director Nelson James Larry was granted 10,665 shares (SEC Form 4)
- Director Dickson Kristine was granted 10,665 shares (SEC Form 4)
- Director Ellinger Deborah G was granted 10,665 shares (SEC Form 4)
- SEC Form 8-K filed by Chewy Inc.
- General Counsel & Secretary Hu Da-Wai sold $81,915 worth of shares (4,203 units at $19.49), closing all direct ownership in the company (SEC Form 4)
- Chewy Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Chewy downgraded by MoffettNathanson
Latest LOGC
- ContextLogic Appoints Seth Siegel as Senior Advisor
- ContextLogic Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CFO & COO Stewart Scott Matthew bought $97,600 worth of shares (10,000 units at $9.76), increasing direct ownership by 20% to 60,000 units (SEC Form 4)
- Director Levy Paul S bought $118,548 worth of shares (12,926 units at $9.17) (SEC Form 4)
- Director Levy Paul S bought $899,618 worth of shares (99,428 units at $9.05) (SEC Form 4)
- Director Levy Paul S bought $232,344 worth of shares (25,693 units at $9.04) (SEC Form 4)
- SEC Form 4 filed by CFO & COO Stewart Scott Matthew
- SEC Form 3 filed by new insider Stewart Scott Matthew
- ContextLogic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- ContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating Officer